Screener
Pacira BioSciences, Inc. PCRX Q2 2026 earnings
Reported August 4, 2026 · After market close
Revenue$192.4MBeat by $1.3M
EPS$0.73Beat by $0.08
Revenue estimate$191.1M
EPS estimate$0.65
“The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy across the business. Just 18 months into the initiative, we are delivering meaningful progress against each of our strategic objectives to drive long-term growth and create significant value. The quarter was also highlighted by our recently closed transaction with Zimmer Biomet, which positions iovera®° to reach its full global potential while preserving Pacira's participation in its future success and further sharpening our focus as an innovation-driven biopharmaceutical company.”
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$182.2M
EPS estimate$0.76
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Pacira BioSciences, Inc. report Q2 2026 earnings?
- Pacira BioSciences, Inc. (PCRX) reported Q2 2026 earnings on August 4, 2026 after market close.
- What were Pacira BioSciences, Inc.'s Q2 2026 revenue and EPS?
- Pacira BioSciences, Inc. reported revenue of $192.4M and eps of $0.73 for Q2 2026.
- Did Pacira BioSciences, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $191.1M by $1.3M. EPS beat the consensus estimate of $0.65 by $0.08.
- How did Pacira BioSciences, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 6.2% from $181.1M a year earlier and eps declined 1.4% from $0.74.
- Where can I find Pacira BioSciences, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-052527) and the 10-Q periodic report (0001628280-26-052635) directly on SEC EDGAR. The filing index links above go to sec.gov.
